NEW YORK (GBI Research), 20 June 2012 - The pharmaceutical companies are paying more attention than ever before to their supply chains as they attempt to boost profits and clamp down on fake drugs, states a new report by healthcare industry analysts GBI Research.
The report* examines the growing importance of strategic supply chain management in maximising revenue for global pharmaceutical companies, and how this is prompting the revision of traditional business models.
International pharmaceutical corporations are starting to tailor supply chains to products based on market demand and production costs. While manufacturing is commonly out-sourced to emerging economies where labor expenses are less substantial, branded products are produced closer to customer bases in developed countries as profit margins are higher and transportation costs lower.
These companies are also employing third-party logistics firms to improve flexibility in times of fluctuating demand. When drug requirements drop, pharmaceutical firms can simply reduce the order volume, rather than rendering costly in-house facilities inoperative.
GBI Research’s latest report also explains how developments in transportation methods are combating counterfeit drugs in the pharmaceutical industry – primarily through the implementation of Radio-Frequency Identification (RFID).
In the US, product callbacks have increased steadily over the last decade, with the Food and Drug Administration (FDA) recalling 1,742 drugs in 2009 alone. This occurs for a number of reasons including poor quality packaging, defective labelling and contamination.
As RFID devices are embedded in product packs and scanned by special readers, they eliminate human error as well as the need to replace labelling damaged in transit. But perhaps the most prominent quality of this technology is the capacity to store comprehensive and encrypted data, therefore reducing the possibility of fake medications entering the supply chain.
Traditionally, counterfeit drugs are manufactured in huge quantities and enter the system with bogus batch numbers and product codes that are identical to legitimate originals. Once in the supply chain these fakes are very difficult to recall, resulting in unnecessary expense for the firm and damaging public opinion. RFID is an important weapon in tackling this problem.
* Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits
This report analyzes the overall Supply Chain Management (SCM) scenario and provides profiles of the leading participants in the pharmaceutical supply chain in the US.
This report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com